阿斯利康2024年总收入超540亿美元 两款肿瘤药涉嫌逃税,称将全力配合中国相关部门

每日经济新闻
06 Feb

2月6日,阿斯利康披露2024年第四季度以及全年财报。数据显示,过去一年公司总收入达到540.73亿美元,同比增长21%;核心每股收益增长19%至8.21美元。中国市场方面,公司总营收实现11%双位数增长,达到64亿美元,占全球收入12%。但相比过去几年的增速有所放缓,特别是在去年第四季度,中国市场的收入按固定汇率CER计算同比下降3%。阿斯利康解释称,这主要受到呼吸道疾病药物需求下降及年底医院...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10